Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohort
Alimentary Pharmacology & Therapeutics2019Vol. 49(10), pp. 1323–1333
Citations Over TimeTop 1% of 2019 papers
Bernhard Scheiner, Martha M. Kirstein, Florian Hucke, Fabian Finkelmeier, Kornelius Schulze, Johann von Felden, Sandra Koch, Philipp Schwabl, Jan B. Hinrichs, Fredrik Waneck, Oliver Waidmann, Thomas Reiberger, Christian Müller, Wolfgang Sieghart, Michael Trauner, Arndt Weinmann, Henning Wege, Jörg Trojan, Markus Peck‐Radosavljevic, Arndt Vogel, Matthias Pinter
Abstract
Programmed cell death protein-1-targeted immunotherapy with nivolumab or pembrolizumab showed promising efficacy and safety in patients with advanced hepatocellular carcinoma, including subjects with Child-Pugh stage B and patients with intensive pretreatment.
Related Papers
- → A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes(2016)117 cited
- → Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases(2018)92 cited
- → Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment(2023)13 cited
- → Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(2023)7 cited
- → Porównanie pośrednie wyników leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą niwolumabu lub pembrolizumabu – analiza wieloośrodkowa(2020)1 cited